CHMP adopts positive opinion for the marketing authorization of Bayer's (BAYN GY) Finerenone for patients with heart failure with left ventricular ejection fraction ≥40%
Importance
Level 1
#GERMANY#EUROPE#BAYER AG#BAYN.GY#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BAYN#EURO STOXX 50#DAX 40 INDEX